Immunocore Holdings (IMCR) Equity Average (2020 - 2026)

Immunocore Holdings has disclosed Equity Average across 7 years of filings, most recently posting $387.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at $387.4 million, up 4.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $387.4 million (up 4.8% YoY), and the FY2025 annual result was $370.9 million, up 1.67% from the prior year.
• Equity Average came in at $387.4 million for Q1 2026 at Immunocore Holdings, roughly flat from $388.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $392.5 million in Q3 2025 to a low of $279.1 million in Q4 2022.
• The 5-year median for Equity Average is $366.3 million (2024), against an average of $361.3 million.
• Across the five-year window, Equity Average soared 83.42% in 2022 and grew 1.49% in 2025, its largest moves.
• Immunocore Holdings' Equity Average stood at $279.1 million in 2022, then grew by 29.85% to $362.4 million in 2023, then grew by 1.89% to $369.3 million in 2024, then grew by 5.29% to $388.8 million in 2025, then decreased by 0.37% to $387.4 million in 2026.
• The last three Equity Average figures came in at $387.4 million (Q1 2026), $388.8 million (Q4 2025), and $392.5 million (Q3 2025), per Business Quant data.